{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/CADL/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-18T16:00:36.621Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":7191,"canonical_name":"Candel Therapeutics, Inc.","cik":"0001841387","uei":null,"lei":null,"duns":null,"ticker":"CADL"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35,"clinical":1},"count":36,"timeline":[{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-10-02","url_slug":"/sec/cik-0001841387/4/0001193125-26-412658","accession_number":"0001193125-26-412658","importance":30},{"ts":"2026-09-11","kind":"sec.insider.s","reporter":"Tak Paul Peter","title":"Chief Executive Officer","shares":59379,"price_per_share":10.4564,"usd_value":620891,"security_title":"Common Stock","importance":35.6208905756},{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-09-11","url_slug":"/sec/cik-0001841387/4/0001873905-26-000002","accession_number":"0001873905-26-000002","importance":30},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Tak Paul Peter","title":"Chief Executive Officer","shares":220866,"price_per_share":11.4997,"usd_value":2539893,"security_title":"Common Stock","importance":37.5398927402},{"ts":"2026-09-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Candel Therapeutics, Inc. — 2026-09-10","url_slug":"/sec/cik-0001841387/8-k/0001193125-26-387310","accession_number":"0001193125-26-387310","importance":35},{"ts":"2026-09-10","kind":"sec.filing","form_type":"144","title":"144 — Candel Therapeutics, Inc. — 2026-09-10","url_slug":"/sec/cik-0001841387/144/0001950047-26-009295","accession_number":"0001950047-26-009295","importance":30},{"ts":"2026-09-10","kind":"sec.filing","form_type":"3","title":"3 — Candel Therapeutics, Inc. — 2026-09-10","url_slug":"/sec/cik-0001841387/3/0001193125-26-387919","accession_number":"0001193125-26-387919","importance":30},{"ts":"2026-09-10","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-09-10","url_slug":"/sec/cik-0001841387/4/0001193125-26-387924","accession_number":"0001193125-26-387924","importance":30},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Tak Paul Peter","title":"Chief Executive Officer","shares":125000,"price_per_share":1.55,"usd_value":193750,"security_title":"Common Stock","importance":15.19375},{"ts":"2026-09-09","kind":"sec.filing","form_type":"8-K","title":"8-K — Candel Therapeutics, Inc. — 2026-09-09","url_slug":"/sec/cik-0001841387/8-k/0001193125-26-386561","accession_number":"0001193125-26-386561","importance":35},{"ts":"2026-08-19","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-08-19","url_slug":"/sec/cik-0001841387/4/0001923794-26-000004","accession_number":"0001923794-26-000004","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"144","title":"144 — Candel Therapeutics, Inc. — 2026-08-17","url_slug":"/sec/cik-0001841387/144/0001950047-26-008263","accession_number":"0001950047-26-008263","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Candel Therapeutics, Inc. — 2026-08-13","url_slug":"/sec/cik-0001841387/10-q/0001193125-26-347980","accession_number":"0001193125-26-347980","importance":45},{"ts":"2026-08-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Candel Therapeutics, Inc. — 2026-08-13","url_slug":"/sec/cik-0001841387/8-k/0001193125-26-347957","accession_number":"0001193125-26-347957","importance":35},{"ts":"2026-07-27","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Candel Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001841387/schedule-13g/0002012383-26-002278","accession_number":"0002012383-26-002278","importance":55},{"ts":"2026-07-08","kind":"sec.filing","form_type":"3","title":"3 — Candel Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001841387/3/0002139479-26-000003","accession_number":"0002139479-26-000003","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-07-08","url_slug":"/sec/cik-0001841387/4/0002139479-26-000004","accession_number":"0002139479-26-000004","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001841387/4/0001909680-26-000002","accession_number":"0001909680-26-000002","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001841387/4/0001923794-26-000002","accession_number":"0001923794-26-000002","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001841387/4/0001979825-26-000006","accession_number":"0001979825-26-000006","importance":30},{"ts":"2026-06-29","kind":"sec.form144","reporter":"FRANCESCA BARONE","title":"Officer","shares":23447,"usd_value":229546,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006597","importance":40.045909226},{"ts":"2026-06-29","kind":"sec.form144","reporter":"SESHU P TYAGARAJAN","title":"Officer","shares":7000,"usd_value":68530,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006607","importance":40.013706},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Barone Francesca","title":"Chief Scientific Officer","shares":23447,"price_per_share":10.0554,"usd_value":235769,"security_title":"Common Stock","importance":35.2357689638},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Tyagarajan Seshu","title":"Chief Technology Officer","shares":7000,"price_per_share":10.0216,"usd_value":70151,"security_title":"Common Stock","importance":35.0701512},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Candel Therapeutics, Inc. — 2026-06-29","url_slug":"/sec/cik-0001841387/144/0001950047-26-006597","accession_number":"0001950047-26-006597","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Candel Therapeutics, Inc. — 2026-06-29","url_slug":"/sec/cik-0001841387/144/0001950047-26-006607","accession_number":"0001950047-26-006607","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"8-K","title":"8-K — Candel Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001841387/8-k/0001841387-26-000009","accession_number":"0001841387-26-000009","importance":35},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001841387/4/0001873465-26-000002","accession_number":"0001873465-26-000002","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001841387/4/0001979825-26-000004","accession_number":"0001979825-26-000004","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001841387/4/0002013423-26-000004","accession_number":"0002013423-26-000004","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — Candel Therapeutics, Inc. — 2026-06-24","url_slug":"/sec/cik-0001841387/4/0001867450-26-000002","accession_number":"0001867450-26-000002","importance":30},{"ts":"2026-06-22","kind":"clinical.trial","reporter":"Candel Therapeutics, Inc.","title":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07660094","excerpt":"[\"Non-squamous, Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-06-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Candel Therapeutics, Inc. — 2026-06-16","url_slug":"/sec/cik-0001841387/8-k/0001841387-26-000007","accession_number":"0001841387-26-000007","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Candel Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001841387/8-k/0001193125-26-226751","accession_number":"0001193125-26-226751","importance":35},{"ts":"2026-05-14","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Candel Therapeutics, Inc. — 2026-05-14","url_slug":"/sec/cik-0001841387/10-q/0001193125-26-222904","accession_number":"0001193125-26-222904","importance":45},{"ts":"2026-05-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Candel Therapeutics, Inc. — 2026-05-14","url_slug":"/sec/cik-0001841387/8-k/0001193125-26-222892","accession_number":"0001193125-26-222892","importance":35}]}